Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236977 | 0.86 | SMN1; SMN2 (0.34) | DPP4L3MBTL1 | |
| SCHEMBL5239768 | 0.85 | DPP4 (0.34) | DPP4AAK1PTGS1TSHRTDP1 | |
| SCHEMBL5235534 | 0.84 | DPP4 (0.35) | DPP4AAK1 | |
| SCHEMBL6108503 | 0.83 | DPP4 (0.33) | DPP4AAK1TSHRTDP1L3MBTL1 | |
| SCHEMBL6109406 | 0.82 | DPP4 (0.32) | DPP4PTGS1 | |
| SCHEMBL5235402 | 0.82 | PTGS1 (0.36) | DPP4AAK1PTGS1MAPTTSHR | |
| Hydrochloric Acid SCHEMBL5239499 | 0.82 | DPP4 (0.43) | DPP4AAK1 | |
| SCHEMBL5233036 | 0.80 | RORC (0.37) | DPP4AAK1MAPTL3MBTL1 | |
| SCHEMBL6109405 | 0.80 | GRN (0.32) | AAK1PTGS1 | |
| SCHEMBL5239288 | 0.78 | TSHR (0.36) | AAK1TSHRTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885AAK1 2000/4885PTGS1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.